Leakage-Controlled Multimodal Learning for Diagnosis and Progression Prediction in Alzheimer's Disease Research
Abstract
Alzheimer's disease prediction involves irregular visits, heterogeneous measurements and incomplete modalities. This study presents a multimodal multitask framework combining an adapted SFCN MRI encoder, four causal clinical Transformers, shared fusion and task-specific ODE-GRU dynamics. Fine-tuning and LoRA adapt the final two MRI blocks. Task-DRO balances task losses, while Group-CVaR targets cohort and comorbidity strata. Branch-specific input controls, subject-grouped partitions and empirical causality checks support longitudinal evaluation. Across 2,649 subjects and 17,317 visits from ADNI, OASIS-2 and MIRIAD, internal validation yields diagnosis, stage-1 progression and first-stage-1-visit progression AUROCs of 0.935 +/- 0.002, 0.884 +/- 0.003 and 0.870 +/- 0.005, respectively (mean +/- SD across three seeds). Corresponding hybrid AUROCs are 0.951, 0.909 and 0.896. Next-visit MMSE mean absolute error (MAE) is 1.61 points; worst-stratum diagnosis AUROC is 0.827 +/- 0.008. Sampled ADNI explanations identify task-specific input dependence. OASIS-3 external validation yields network and hybrid diagnosis AUROCs of 0.763 and 0.767, hybrid next-visit progression AUROC of 0.764, diagnosis calibration error decreasing from 0.197 to 0.052, and next-visit MMSE MAE of 0.86. Seed-42 paired ablations of six components yield pooled diagnosis and progression AUROC differences between -0.004 and +0.004; removing clinical encoder inputs lowers diagnosis AUROC by 0.272. The framework integrates longitudinal prediction, missing-modality handling, auxiliary comorbidity modelling and subgroup evaluation within a common pipeline.
Figures & tables
| Method | Year | M | CT | D+P | Com | R | Task (metric) | Reported |
| Multimodal Diagnosis and Conversion | ||||||||
| Zhang & Shen [ 26 ] | 2012 | ✓ | MCI conv. (AUC) | 0.77 † | ||||
| Lee et al. [ 27 ] | 2019 | ✓ | MCI AD conv. (AUC) | 0.86 | ||||
| Zhou et al. [ 28 ] | 2019 | ✓ | ✓ | sMCI/pMCI (AUC) | 0.755 | |||
| Huang [ 29 ] | 2023 | ✓ | Diagnosis, ADNI (Acc) | 0.838 | ||||
| Afifi et al. [ 23 ] | 2026 | – | – | – | – | – | Review | – |
| Source | Subjects | Visits | MRI acquisitions |
| OASIS-2 | 150 | 373 | 373 |
| MIRIAD | 69 | 523 | 708 |
| ADNI | 2,430 | 16,421 | 0 |
| Total | 2,649 | 17,317 | 1,081 |
| Cohort | Source labels | Binary label (stage) |
| OASIS-2 | CDR 0 / 0.5 / 1 | 0 = CDR 1 (0, 1) 1 = CDR 1 (2) |
| MIRIAD | Control, AD | 0 = control (0) 1 = AD (2) |
| ADNI | CN, MCI, Dementia | 0 = CN (0) 1 = Dementia (2) MCI: excluded (1) |
| Branch | Prohibited inputs |
| Diagnosis | CDR, MMSE, all cognitive/functional tests, current stage |
| Forecast | CDR (and its sum of boxes) |
| MMSE | CDR, MMSE and its rates, composite scores that contain MMSE |
| Atrophy | CDR, nWBV, hippocampal volume and their rates |
| Metric | Value [95% CI] | 3 seeds |
| Diagnosis (cohort-defined binary endpoint) | ||
| AUROC, network | 0.936 [0.925, 0.948] | 0.935 0.002 |
| AUROC, hybrid | 0.951 [0.941, 0.961] | 0.951 0.001 |
| Average precision, network / hybrid | 0.917 / 0.936 | 0.915 / 0.936 |
| Balanced accuracy | 0.870 | 0.865 0.008 |
| ECE, raw calibrated | 0.135 0.031 | 0.134 0.025 |
| Task / metric | Network | Tabular | Hybrid | Logistic |
| Diagnosis AUROC ( ) | 0.763 | 0.762 | 0.767 | 0.787 |
| Progression AUROC ( ) | 0.733 | 0.768 | 0.764 | 0.710 |
| Current MMSE MAE / ( ) | 1.80 / | – | – | – |
| Next-visit MMSE MAE / ( ) | 0.86 / 0.24 | – | – | – |
| Diagnosis ECE, raw calibrated | 0.197 0.052 | – | – | – |
| Progression ECE, raw calibrated | 0.401 0.303 | – | – | – |
| Experiment | Diagnosis | 3-year conversion AUROC | Cognition / atrophy | Comorbidity (ADNI) | ||||
| AUROC | MCI visits | sMCI/pMCI | MMSE MAE | Next MMSE MAE | Next atrophy | Mean AUROC | Worst-stratum dx | |
| Full model | 0.936 | 0.881 | 0.872 | 1.577 | 1.615 | 0.828 | 0.565 | 0.819 |
| Component ablations | ||||||||
| w/o Task-DRO | 0.937 | 0.880 | 0.869 | 1.554 | 1.599 | 0.833 | 0.577 | 0.834 |
| w/o Group-CVaR | 0.937 | 0.885* | 0.874 | 1.597 | 1.619 | 0.834 | 0.565 | 0.828 |
| w/o contrastive | 0.938 | 0.884 | 0.871 | 1.557 | 1.594 | 0.839 | 0.540 | 0.837 |
| Encoder | Dx | MCI | sMCI | Params (total/trainable) | s/epoch | 5-fold time |
| SFCN + LoRA (main) | 0.936 | 0.881 | 0.872 | 6.97M / 4.02M | 187 | 5.33 h |
| SFCN w/o LoRA | 0.938 | 0.880 | 0.875 | 6.91M / 3.96M | 217 | 5.32 h |
| ResNet-50 + LoRA | 0.932 | 0.884 | 0.871 | 50.50M / 4.34M | 208 | 6.18 h |
| Cohort | Visits | Network | Hybrid |
| ADNI | 6,469 | 0.947 | 0.961 |
| OASIS-2 | 373 | 0.629 | 0.803 |
| MIRIAD | 523 | 0.424 | 0.456 |
| Condition | Cases | Full | w/o CVaR | 3-seed mean |
| Depression | 518 | 0.605 | 0.615 | 0.598 |
| Diabetes | 162 | 0.512 | 0.540 | 0.551 |
| Hypertension | 835 | 0.547 | 0.544 | 0.547 |
| Coronary artery disease | 223 | 0.634 | 0.637 | 0.636 |
| Stroke | 74 | 0.570 | 0.546 | 0.588 |
| Hyperlipidaemia | 801 | 0.519 | 0.523 | 0.521 |
| Worst-stratum diagnosis | Worst-stratum conversion | Hardest comorbidity | Comorbidity mean | |
| Full model | 0.819 (COPD) | 0.765 (stroke) | 0.512 (diab.) | 0.565 |
| w/o CVaR | 0.828 (COPD) | 0.768 (stroke) | 0.523 (hyperl.) | 0.565 |
| Seed SD | 0.008 | 0.029 | 0.006 | 0.010 |
| Mean of 3 worst strata: diagnosis 0.883, conversion 0.785 (full); 0.889, 0.799 (no CVaR) | ||||
| Disparity (best worst): diagnosis 0.135, conversion 0.145 (full); 0.123, 0.144 (no CVaR) | ||||